Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853017 · ClinicalTrials.gov registry record · Phase 1
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
A Phase 1 study, sponsored by Elicio Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04853017 is a Phase 1 study that has completed, run by Elicio Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT04853017, a Phase 1 study, has completed, sponsored by Elicio Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.
Interventions
- DRUG ELI-002 2P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04853017
The ClinicalTrials.gov registry entry for NCT04853017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elicio Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ELI-002 2P is the first listed.
NCT04853017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04853017 about?
NCT04853017 is a clinical study titled "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors". This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects...
What is the current status of trial NCT04853017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-10-04. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT04853017?
The interventions under investigation include: ELI-002 2P (DRUG).
Who is sponsoring clinical trial NCT04853017?
This trial is sponsored by Elicio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.